 you know, right before Q3, which means we'd be on track for an antifungal trial and to be accepted Q4 and to launch Q1 2025. So, you know, TCP-008 is just out there killing it. And, you know, we're in a great place with the core assets. And then on top of that, all these other assets that are coming on board for us,